Drug Profile
Research programme: peripheral vascular disease gene therapy - Boehringer Ingelheim/Inovio
Alternative Names: Peripheral vascular disease gene therapy - Boehringer Ingelheim/InovioLatest Information Update: 18 Aug 2009
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Inovio Biomedical Corporation
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Peripheral vascular disorders
Most Recent Events
- 18 Aug 2009 Discontinued - Preclinical for Peripheral vascular disorders in USA (unspecified route)
- 04 Apr 2005 Genetronics Biomedical Corporation is now called Inovio Biomedical Corporation
- 31 Aug 2004 This programme is still in active development